New combo therapy aims to keep lymphoma in check after transplant
NCT ID NCT04491370
First seen Apr 22, 2026 · Last updated Jun 12, 2026 · Updated 6 times
Summary
This study tests whether adding a targeted drug called polatuzumab vedotin after a stem cell transplant can safely control B-cell and Hodgkin lymphoma. About 20 adults whose lymphoma has returned or not responded to prior treatment will take part. The goal is to see if the drug can prevent the cancer from coming back without causing severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical Center
RECRUITINGValhalla, New York, 10595, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.